ChengDa Pharmaceuticals Co. Ltd. - Asset Resilience Ratio
ChengDa Pharmaceuticals Co. Ltd. (301201) has an Asset Resilience Ratio of 32.14% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ChengDa Pharmaceuticals Co. Ltd. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of ChengDa Pharmaceuticals Co. Ltd..
Liquid Assets Composition Over Time
This chart breaks down ChengDa Pharmaceuticals Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does ChengDa Pharmaceuticals Co. Ltd. carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥755.58 Million | 32.14% |
| Total Liquid Assets | CN¥755.58 Million | 32.14% |
Asset Resilience Insights
- Very High Liquidity: ChengDa Pharmaceuticals Co. Ltd. maintains exceptional liquid asset reserves at 32.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ChengDa Pharmaceuticals Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare ChengDa Pharmaceuticals Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for ChengDa Pharmaceuticals Co. Ltd. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for ChengDa Pharmaceuticals Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.49% | CN¥270.08 Million ≈ $39.52 Million |
CN¥2.35 Billion ≈ $343.86 Million |
-27.81pp |
| 2024-12-31 | 39.31% | CN¥957.65 Million ≈ $140.13 Million |
CN¥2.44 Billion ≈ $356.53 Million |
+5.85pp |
| 2022-12-31 | 33.46% | CN¥776.89 Million ≈ $113.68 Million |
CN¥2.32 Billion ≈ $339.77 Million |
-- |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and A… Read more